Dual specificity antibody fusions

Patent metadata

Field	Value
Publication number	US-11427650-B2
Application number	US-201916124650-A
Country	US
Kind code	B2
Filing date	Jan 21, 2019
Priority date	Sep 26, 2007
Publication date	Aug 30, 2022
Grant date	Aug 30, 2022

Abstract

The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

First claim

The invention claimed is:

1. An albumin binding antibody, comprising the sequence given in SEQ ID NO: 56 for CDR-H1, the sequence given in SEQ ID NO: 57 for CDR-H2, the sequence given in SEQ ID NO: 58 for CDR-H3, the sequence given in SEQ ID NO: 59 for CDR-L1, the sequence given in SEQ ID NO: 60 for CDR-L2, and the sequence given in SEQ ID NO: 61 for CDR-L3.

2. The albumin binding antibody of claim 1 , further comprising a heavy chain VH domain having the sequence given in SEQ ID NO: 52.

3. The albumin binding antibody of claim 2 , further comprising a light chain VL domain having the sequence given in SEQ ID NO: 53.

4. The albumin binding antibody of claim 1 , wherein the antibody is a whole antibody or a functionally active fragment or derivative thereof.

5. The albumin binding antibody of claim 1 , wherein the antibody is a Fab, a modified Fab, a Fab′, a F(ab′)2, Fv, a scFv, a bi, a tri, or a tetra-valent antibody, a Bis-scFv, a diabody, a triabody, a tetrabody, or an epitope-binding fragment thereof.

6. The albumin binding antibody of claim 1 , wherein the antibody is multispecific.

7. The albumin binding antibody of claim 1 , wherein the antibody is conjugated to an antibody, a protein, or a molecule.

8. The albumin binding antibody of claim 1 , wherein the antibody is humanised.

9. The albumin binding antibody of claim 1 , wherein the albumin is human serum albumin.

10. The albumin binding antibody of claim 1 , wherein the antibody has a binding affinity for albumin of about 2 μM or better.

11. A pharmaceutical composition, comprising the albumin binding antibody of claim 1 .

12. The pharmaceutical composition of claim 11 , wherein the composition is for the treatment of a disease or disorder;
wherein the disease or disorder is an inflammatory disease or disorder, an immune disease or disorder, a fibrotic disorder and/or a cancer;
wherein the inflammatory disease or disorder and/or the immune disease or disorder comprise rheumatoid arthritis, psoriatic arthritis, still's disease, Muckle Wells disease, psoriasis, Crohn's disease, ulcerative colitis, SLE (Systemic Lupus Erythematosus), asthma, allergic rhinitis, atopic dermatitis, multiple sclerosis, vasculitis, Type I diabetes mellitus, transplantation and graft-versus-host disease;
wherein the fibrotic disorder comprises idiopathic pulmonary fibrosis (IPF), systemic sclerosis (or scleroderma), kidney fibrosis, diabetic nephropathy, IgA nephropathy, hypertension, end-stage renal disease, peritoneal fibrosis, liver cirrhosis, age-related macular degeneration (ARMD), retinopathy, cardiac reactive fibrosis, scarring, keloids, burns, skin ulcers, angioplasty, coronary bypass surgery, arthroplasty and cataract surgery; and
wherein the cancer comprises (i) a malignant new growth that arises from epithelium, found in skin or the lining of breast, ovary, prostate, lung, kidney, pancreas, stomach, bladder or bowel and/or (ii) bone, liver, lung or brain cancer.

Assignees

• Ucb Pharma Sa
• UCB Biopharma SRL

Inventors

• Humphreys David Paul
• Dave Emma
• Griffin Laura
• Heywood Sam Philip

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• C07K16/468 Primary

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• A61P13/12

  of the kidneys · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title